NCT04416646Completed
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma: Observational Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 12 May 2020
- Start date
- 27 Feb 2019
- Primary completion date
- 26 Jun 2023
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- Diseases
- Kidney cancer
- NCT number
- NCT04416646
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 27 Feb 2019 to the primary completion date, 26 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Serious comorbidities or cognitive impairment, which may interfere with cabozantinib administration and/or patient's follow up, as judged by the treating physician
Other
- Inability to swallow cabozantinib tablets
- Absence of a reliable caregiver, as judged by the treating physician
Who the study is looking for
- Age 70 years
- Histological diagnosis of Renal Cell Carcinoma (any histology, with the exclusion of urothelial carcinomas)
- Locally advanced disease or metastatic disease (any site, measurable or non- measurable lesions), progressing after at least one line of VEGFR-targeted therapy (as per official registration of the drug at AIFA, in case of extension to first-line treatment, TKI-naïve patients will also be eligible), with or without previous exposure to check-point inhibitors.
- Life expectancy of at least 3 months
- Adequate hepatic, renal and bone marrow function as judged by the treating oncologist.
- Written informed consent
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Oncologico Veneto Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.